Welcome to our dedicated page for 10X Genomics news (Ticker: TXG), a resource for investors and traders seeking the latest updates and insights on 10X Genomics stock.
10x Genomics, Inc. (NASDAQ: TXG) is a life science technology company focused on single cell and spatial biology, and this news page aggregates company-related announcements, research collaborations and financial updates. The company’s integrated research solutions include instruments, consumables and software that are used by academic and translational researchers and biopharmaceutical companies to study complex biological systems.
News about 10x Genomics often highlights developments in its technology platforms, such as new single cell instruments, assays and spatial workflows. Recent announcements have described launches and enhancements within the Chromium single cell portfolio, including instruments and assays designed to make high-performance single cell analysis more accessible and scalable. The company has also reported new capabilities on its Xenium spatial platform, including spatial multiomic workflows that enable simultaneous RNA and protein detection on tissue sections.
Another key theme in TXG news is large-scale research collaborations. 10x Genomics has announced partnerships with academic medical centers, cancer institutes, research consortia and nonprofit organizations to apply its single cell and spatial technologies in areas such as autoimmune disease, oncology, immuno-oncology and transplantation. These initiatives often involve generating high-resolution molecular maps of cells and tissues, linking them with clinical data and exploring potential diagnostic or clinical reporting frameworks.
Investors and researchers following TXG news will also find periodic financial results, preliminary revenue updates and participation in healthcare and investor conferences. Together, these items provide insight into the company’s product adoption, geographic reach, research impact and engagement with the broader scientific and investment communities. Users interested in 10x Genomics can use this page to review company press releases and related coverage over time.
10x Genomics (TXG) has announced that it will release its financial results for Q4 and full year ended December 31, 2020, after the market close on February 17, 2021. A conference call to discuss the results and company outlook will begin at 1:30 PM PT. The event will be accessible via webcast on the company's website and archived for replay for 45 days. 10x Genomics focuses on life science technology, providing solutions that enhance biological understanding, serving major global research institutions and pharmaceutical companies.
10x Genomics (Nasdaq: TXG) will participate in the 39th Annual J.P. Morgan Virtual Healthcare Conference, scheduled for January 11, 2021, at 7:00 a.m. PT / 10:00 a.m. ET. The company's management will present key information, and interested parties can access a live and archived webcast on their Investors page.
10x Genomics develops integrated solutions for biological research, with products widely adopted by leading research institutions and pharmaceutical companies.
10x Genomics, Inc. (TXG) reported Q3 2020 revenue of $71.8 million, a 17% increase year-over-year and a 67% increase from Q2 2020. The company made significant acquisitions of ReadCoor and CartaNA, enhancing its capabilities in In Situ analysis. Despite revenue growth, operating expenses surged 124% to $122.7 million, leading to an operating loss of $65.3 million and a net loss of $65.8 million. The company has withdrawn its full-year revenue guidance due to ongoing COVID-19 uncertainties.
10x Genomics (Nasdaq: TXG) will participate in the Stifel Virtual Healthcare Conference on November 16 at 11:40 a.m. PT. The presentation will be accessible via a live and archived webcast on the company’s investors page.
10x Genomics offers advanced products for biological analysis, utilized by 97 of the top 100 research institutions and 19 of the top 20 pharmaceutical companies. With over 1,750 citations in research, the company holds a patent portfolio of more than 825 patents and applications.
10x Genomics (TXG) will report its third-quarter financial results on November 10, 2020, post-market. A conference call will follow at 2:00 PM PT to discuss outcomes, business developments, and future outlook.
The event will be available for live audio streaming on the company’s website, with a recording accessible for 45 days thereafter. 10x Genomics specializes in life science technologies, offering comprehensive solutions for biological analysis, widely adopted by leading research institutions and pharmaceutical companies.
10x Genomics (Nasdaq: TXG) announced a definitive agreement to acquire ReadCoor, a developer of In Situ technologies, for $350 million in cash and stock. This follows the acquisition of CartaNA AB, enhancing 10x's capabilities in In Situ RNA analysis. Together, these acquisitions are expected to develop comprehensive intellectual property and technology in the emerging In Situ field, potentially establishing a new technology platform and broadening customer applications. The ReadCoor acquisition is anticipated to complete later this month, subject to shareholder approval.
10x Genomics, Inc. (NASDAQ: TXG) announced the successful closing of a public offering for 4,600,000 shares of its Class A common stock, including the full exercise of an underwriters’ option for an additional 600,000 shares. Priced at $110.00 per share, the total gross proceeds amounted to $506 million prior to underwriting discounts and expenses. J.P. Morgan Securities LLC, BofA Securities, and Cowen and Company acted as lead managers. Registration statements for this offering were effective as of September 10, 2020.
10x Genomics (Nasdaq: TXG) has announced the commercial shipping of its Chromium Single Cell Multiome ATAC + Gene Expression solution, the first product to simultaneously profile a cell's epigenome and transcriptome. This innovative approach enhances research capabilities by directly linking epigenetic programs to gene expression, improving understanding of cell functionality and disease mechanisms. Early adopters include Stanford and Mt. Sinai, emphasizing its potential in studying immune response to cancer and neuropsychiatric diseases.
10x Genomics, Inc. (NASDAQ: TXG) announced a public offering of 4,000,000 shares of its Class A common stock, priced at $110.00 each. An additional 600,000 shares may be purchased by underwriters. The offering is expected to close on September 15, 2020, pending customary closing conditions. The underwriting group consists of J.P. Morgan Securities LLC, BofA Securities, and Cowen and Company, with Stifel and William Blair as co-managers. This offering aims to strengthen the company's capital position.
10x Genomics (NASDAQ: TXG) announced a public offering of 3,500,000 shares of its Class A common stock. The offering is underwritten by J.P. Morgan, BofA Securities, and Cowen and Company, with a 30-day option for underwriters to purchase an additional 525,000 shares. A preliminary registration statement has been filed with the SEC but is not yet effective, meaning shares cannot be sold until it is approved. The company aims to raise capital for ongoing business operations.